KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cost of Revenue: 2009-2025

Historic Cost of Revenue for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to $140.1 million.

  • Biomarin Pharmaceutical's Cost of Revenue fell 25.67% to $140.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $577.9 million, marking a year-over-year decrease of 0.71%. This contributed to the annual value of $580.2 million for FY2024, which is 9.05% up from last year.
  • Biomarin Pharmaceutical's Cost of Revenue amounted to $140.1 million in Q3 2025, which was down 6.67% from $150.1 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Cost of Revenue registered a high of $188.5 million during Q3 2024, and its lowest value of $103.5 million during Q3 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Cost of Revenue value was $136.1 million (recorded in 2024), while the average stood at $141.3 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first plummeted by 45.16% in 2021, then spiked by 47.18% in 2024.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Cost of Revenue stood at $119.8 million in 2021, then grew by 22.46% to $146.6 million in 2022, then dropped by 5.94% to $137.9 million in 2023, then declined by 1.30% to $136.1 million in 2024, then decreased by 25.67% to $140.1 million in 2025.
  • Its last three reported values are $140.1 million in Q3 2025, $150.1 million for Q2 2025, and $151.6 million during Q1 2025.